Starpharma Holdings Limited · ASX:SPL
Starpharma — Bell Potter Healthcare Conference 2024
19 slides from Starpharma's conference presentation, Nov 18, 2024
Slide 1: ASX Announcement: Bell Potter Healthcare Conference Presentation
ASX Announcement Bell Potter Healthcare Conference Presentation Melbourne, Australia; 18 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, provides a copy of the prese
Slide 2: Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology
For personal use only ASX : SPL US OTC : SPHRY Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology Bell Potter Healthcare Conference | 18 November 2024 CEO, Cheryl Maley
Slide 3: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements For personal use only This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assura
Slide 4: Our Mission
For personal use only “To help patients with significant illnesses, such as cancer, achieve Our Mission improved health outcomes and quality of life through the application of our unique dendrimer technology.” 3
Slide 5: Starpharma is an Innovative Australian Biotechnology Company
Starpharma is an Innovative Australian Biotechnology Company with 20 Years of Experience in Advancing Dendrimer Technology from the Lab to the Patient For personal use only ASX: SPL Ticker Symbol US OTC: SPHRY Healthcare, Industry/Sector Pharmaceuticals, Biotechnology Market ~A$40M Capitalisation Sh
Slide 6: Starpharma's DEP Platform Technology: What Is It and How Does It Benefit Patients?
Starpharma’s DEP® Platform Technology: What Is It and How Does It Benefit Patients? For personal use only 5
Slide 7: Starpharma – Founders and Experts in Dendrimer Drug Delivery
Starpharma – Founders and Experts in Dendrimer Drug Delivery For personal use only Dendrimers are highly branched (tree-like) macromolecules with a well-defined, 3D structure Clinically validated technology Dendrimer Generations More than 350 patients treated with DEP® across multiple clinical progr
Slide 8: DEP Platform Technology: Versatile and Multifunctional
Starpharma’s DEP® Platform Technology: Versatile and Multifunctional for Delivery of Therapeutics and Diagnostics Multiple Revenue Streams: Maximising Shareholder Returns For personal use only DEP® SN38 and DEP® cabazitaxel: Phase II commercial opportunities to address Clinical unmet needs in oncolo
Slide 9: Starpharma's Oncology Portfolio: Addressing Areas of High Unmet Clinical Need
Starpharma’s Oncology Portfolio: Addressing Areas of High Unmet Clinical Need Three Clinical Assets and Three Pipeline Assets For personal use only Target Product Research Preclinical Phase I Phase II Phase III Strategy indication Ovarian and License/co-develop – DEP® SN38 Phase II results reported
Slide 10: DEP SN38 & DEP cabazitaxel Global Commercial Opportunity
DEP® SN38 & DEP® cabazitaxel Global Commercial Opportunity For personal use only Both assets were developed DEP® SN38 Phase II Results Indication Evaluation using the DEP® technology to improve existing oncology Clinically meaningful outcomes were achieved for patients who Advanced DEP® SN38 were he
Slide 11: DEP SN38 Phase I/II Trial Patients – Advanced, Heavily Pre-treated
DEP® SN38 Phase I/II Trial Patients – Advanced, Heavily Pre-treated, and Most CRC Patients had Progressed Following Prior Treatment with Irinotecan For personal use only BASELINE CHARACTERISTICS COLORECTAL OVARIAN PANCREATIC BREAST OTHER1 TOTAL Subjects enrolled (n, %) 55 (48%) 23 (20%) 15 (13%) 8 (
Slide 12: DEP SN38 Phase II Study Shows Favourable Efficacy and Tolerability
DEP® SN38 Phase II Study Shows Favourable Efficacy and Tolerability Data in Late-Stage Patients Results Presented at the 2024 ASCO Annual Meeting For personal use only Advanced Colorectal Cancer Gastrointestinal Toxicity Profile Significantly Improved with DEP® 14 SN38 Treatment, Compared to Publish
Slide 13: Benefits of DEP Platform Technology Extend to Radiopharmaceuticals
Benefits of Starpharma’s DEP® Platform Technology Extend to Radiopharmaceuticals For personal use only Ability to use a wide range of targeting moieties Site-specific attachment of dendrimer on targeting moiety DEP® dendrimers are precisely manufactured and easily scalable Drug-linker strategy flexi
Slide 14: Addressing the Biodistribution Challenges with DEP Radiotheranostics
Addressing the Biodistribution Challenges of Current Approaches with DEP® Radiotheranostics For personal use only Biodistribution Challenges Starpharma’s DEP® Technology Solution: with Current Approaches: Tumour:Kidney/Organ DEP® HER2 radiodiagnostic: faster Tumour:Kidney ratio highly negative Tumou
Slide 15: Extensive Partnership Experience and Flexible Approach to Collaboration
Extensive Partnership Experience, Broad DEP® Application Opportunity and a Flexible Approach to Collaboration For personal use only R&D collaboration Types of Partnerships Co-development Applicable to a Wide and Collaboration Range of Therapeutic Opportunities Licence Areas Technology access Partner
Slide 16: Well Positioned to Accelerate Product Pipeline and Strategic Growth Initiatives
Well Positioned to Accelerate Product Pipeline and Strategic Growth Initiatives For personal use only 3-Year Summary FY24 FY23 FY22 Multiple Revenue Streams $M $M $M • Licenses and Milestone Payments Revenue and other income 9.8 4.3 5.2 • Marketed Products: VivaGel® BV Loss for the period (8.2) (15.
Slide 17: Recent Strategic Review Confirmed Three Key Focus Areas
Recent Strategic Review Confirmed Three Key Focus Areas to Optimise Shareholder Returns For personal use only 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Increasing revenue, Prioritising DEP® SN38 and DEP® Advancing DEP® strengthening IP posit
Slide 18: Catalysts to Anticipate in The Next Months
Catalysts to Anticipate in The Next 12 Months Poised for Value Creation For personal use only 1) License / collaboration for a DEP® asset to commercialise Over 20 years of experience in advancing dendrimer 2) Radiodiagnostic progress to the clinic technology from the lab to the patient. 3) Strategic
Slide 19: Thank you
For personal use only ASX : SPL US OTC : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Bell Potter Healthcare Conference 2024 on 6ix